ImCheck Therapeutics has dosed the first patient in a Phase I/IIa clinical trial evaluating ICT01, a first-in-class gamma delta T cell-activatingmonoclonal antibody targeting the extracellular domain of Butyrophilin 3A. EVICTION (EValuation of ICT01 in Immuno-ONcology) is a first-in-human, two-part, open-label clinical trial to assess the safety, tolerability and activity of ICT01 as monotherapy and in combination with an immune checkpoint inhibitor in patients with advanced, relapsed/refractory cancer, including both solid and hematologic tumors that express BTN3A.
by eazee-designstudio
Nature Biotechnology has published a study demonstrating Carisma's foundational technology evaluating the potential of human chimeric antigen receptor macrophages (CAR-M) for cancer immunotherapy. The preclinical findings indicate that CAR-M therapy could overcome the key challenges that cell therapies have encountered with solid tumors – limited trafficking to the tumor site, an immunosuppressive tumor microenvironment, and the heterogeneous expression of tumor-associated antigens.
